Biomaterials delivery strategies to repair spinal cord injury by modulating macrophage phenotypes

Abstract

Spinal cord injury (SCI) causes tremendous harm to a patient’s physical, mental, and financial health. Moreover, recovery of SCI is affected by many factors, inflammation is one of the most important as it engulfs necrotic tissue and cells during the early stages of injury. However, excessive inflammation is not conducive to damage repair. Macrophages are classified into either blood-derived macrophages or resident microglia based on their origin, their effects on SCI being two-sided. Microglia first activate and recruit blood-derived macrophages at the site of injury—blood-borne macrophages being divided into pro-inflammatory M1 phenotypes and anti-inflammatory M2 phenotypes. Among them, M1 macrophages secrete inflammatory factors such as interleukin-β (IL-β), tumor necrosis factor-α (TNF-α), IL-6, and interferon-γ (IFN-γ) at the injury site, which aggravates SCIs. M2 macrophages secrete IL-4, IL-10, IL-13, and neurotrophic factors to inhibit the inflammatory response and inhibit neuronal apoptosis. Consequently, modulating phenotypic differentiation of macrophages appears to be a meaningful therapeutic target for the treatment of SCI. Biomaterials are widely used in regenerative medicine and tissue engineering due to their targeting and bio-histocompatibility. In this review, we describe the effects of biomaterials applied to modulate macrophage phenotypes on SCI recovery and provide an outlook.

Calcium Carbonate/Polydopamine Composite Nanoplatform Based on TGF-β Blockade for Comfortable Cancer Immunotherapy

“…Then, the homogenate was placed on ice for 45 min to lyse the cells, and the total protein solution was concentrated through centrifugation at 13,523g for 20 min. The levels of IL-1β, IL-6, TNF-α, and TGF-β in the tumors were measured by ELISA kits. , …”

“…The levels of IL-1β, IL-6, TNF-α, and TGF-β in the tumors were measured by ELISA kits. 53,54 2.14. Statistical Analysis.…”

Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges

“…The survival rate and long-term survival of MSCs in hostile environments remain unresolved issues (144). Gels and scaffolds based on stem cell therapy can deliver MSCs to the site of injury and release MSCs slowly and continuously to the site of injury (145)(146)(147)(148)(149). Tissue engineering strategies can reduce the number of times that MSCs are administered to the patient and reduce the mechanical damage at the site of puncture.…”

Biomaterial‐Based Gene Delivery to Central Nervous System Cells for the Treatment of Spinal Cord Injury

“…[ 158 ] While several studies have demonstrated effective alteration of macrophage gene expression in the injured cord lesion site, the majority have used viral delivery with relatively few using nonviral strategies. Nevertheless, several biomaterial‐based strategies have proven capable of modifying macrophage phenotype [ 159 ] and nonviral delivery as a viable approach to alter macrophage activity and gene expression. For example, chitosan nanoparticles carrying miR‐124 (a mediator of microglia quiesence [ 160 ] ) injected into the injured rat spinal cord significantly reduced the number of ED‐1 positive macrophages in the injury site and were associated with reduced markers of inflammation.…”